Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers

Figures & data

Table 1. Baseline (Day 0) Measures of Immune Response in the 106 Subjects by Sex, Age, and Race

	Sample Size	HI Titer (median, IQR)	VNA Titer (median, IQR)	B-cell ELISPOT* (median, IQR)
Overall	106	1:80 (1:40, 1:280)	1:80 (1:40, 1:320)	11.25 (4.50, 21.75)
Male	41	1:80 (1:80, 1:160)	1:80 (1:40, 1:160)	8.50 (3.00, 19.00)
Female	65	1:160 (1:40, 1:320)	1:160 (1:40, 1:320)	14.50 (5.50, 23.50)
50-54 Years of Age	23	1:160 (1:60, 1:320)	1:160 (1:40, 1:320)	10.00 (3.75, 20.75)
55-59 Years of Age	37	1:160 (1:80, 1:160)	1:80 (1:40, 1:320)	16.50 (5.50, 26.50)
60-64 Years of Age	16	1:80 (1:80, 1:160)	1:80 (1:80, 1:160)	14.75 (7.13, 24.38)
65-69 Years of Age	14	1:120 (1:50, 1:560)	1:120 (1:50, 1:520)	10.50 (7.75, 15.13)
70-74 Years of Age	16	1:80 (1:40, 1:160)	1:80 (1:40, 1:200)	5.75 (1.88, 16.25)

*Spot-forming cells (SFC) per 2 × 10⁵ peripheral blood mononuclear cells (PBMCs).

Figure 1. Algorithm of HI Results across the 106 Subjects by the Changes in Days 0, 28, and 75.

Table 2. Distribution of the 106 Subjects by Changes at Days 0, 28, and 75

Profile, N = 106	Percent of Whole	Age (median, IQR)	% Female
Ceiling Reached; No Response Expected, N = 11	10.4%	59.8 (53.5, 67.9)	63.6%
Vaccine Responsive; No Waning, N = 21	19.8%	61.4 (54.5, 65.0)	57.1%
Vaccine Responsive; Limited Waning, N = 13	12.3%	58.7 (55.3, 60.0)	46.2%
Vaccine Responsive; Waning at least 4-fold, N = 3	2.8%	60.7 (57.4, 66.5)	100.0%
Vaccine Unresponsive; Late Elevation, N = 2	1.8%	68.4 (65.6, 71.1)	50.0%
Vaccine Unresponsive; No Waning, N=48	45.3%	59.7 (56.6, 69.0)	66.7%
Vaccine Unresponsive; Limited Waning, N=8	7.5%	55.8 (53.6, 62.2)	50.0%

Figure 2. Behavior of HI Titers across the 106 Subjects over Days 0, 28, and 75.

Table 3. Distribution of the Hemagglutination-Inhibition Assay, Viral Neutralization Assay and B-cell ELISPOT Results

Profile, N = 106	Sample Date	HI Titer (median, IQR)	VNA Titer (median, IQR)	B-cell ELISPOT* (median, IQR)
Ceiling Reached; No Response Expected, N = 11	Day 0	1:640 (1:640, 1:1280)	1:640 (1:640, 1:960)	13.5 (9.8, 23.3)
	Day 28	1:1280 (1:640, 1:1280)	1:1280 (1:640, 1:1280)	35.0 (12.8, 51.8)
	Day 75	1:640 (1:640, 1:1280)	1:1280 (1:640, 1:2560)	27.0 (12.0, 47.0)
Vaccine Responsive; No Waning, N = 21	Day 0	1:80 (1:40, 1:80)	1:80 (1:40, 1:80)	11.5 (2.0, 23.0)
	Day 28	1:320 (1:160, 1:1280)	1:320 (1:320, 1:1280)	38.0 (13.0, 62.0)
	Day 75	1:640 (1:160, 1:1280)	1:640 (1:320, 1:1280)	21.5 (11.0, 31.5)
Vaccine Responsive; Limited Waning, N = 13	Day 0	1:80 (1:40, 1:160)	1:80 (1:40, 1:80)	9.5 (6.0, 20.0)
	Day 28	1:320 (1:320, 1:640)	1:640 (1:320, 1:1280)	37.5 (27.5, 60.0)
	Day 75	1:160 (1:160, 1:320)	1:160 (1:160, 1:1280)	41.0 (26.5, 51.0)
Vaccine Responsive; Waning at least 4-fold, N = 3	Day 0	1:40 (1:25, 1:100)	1:80 (1:45, 1:200)	3.5 (2.3, 6.0)
	Day 28	1:640 (1:480, 1:960)	1:640 (1:480, 1:960)	31.0 (22.0, 33.3)
	Day 75	1:80 (1:60, 1:200)	1:160 (1:100, 1:240)	10.5 (6.3, 20.3)
Vaccine Unresponsive; Late Elevation, N = 2	Day 0	1:100 (1:70, 1:130)	1:60 (1:50, 1:70)	40.8 (19.9, 61.6)
	Day 28	1:120 (1:100, 1:140)	1:120 (1:100, 1:140)	106.8 (55.9, 157.6)
	Day 75	1:480 (1:400, 1:560)	1:240 (1:200, 1:280)	117.0 (62.3, 171.8)
Vaccine Unresponsive; No Waning, N = 48	Day 0	1:160 (1:70, 1:200)	1:160 (1:70, 1:320)	12.5 (4.9, 20.0)
	Day 28	1:160 (1:80, 1:320)	1:160 (1:80, 1:320)	35.0 (17.0, 57.0)
	Day 75	1:160 (1:80, 1:320)	1:160 (1:80, 1:320)	20.3 (8.5, 31.8)
Vaccine Unresponsive; Limited Waning, N = 8	Day 0	1:160 (1:80, 1:200)	1:160 (1:80, 1:200)	14.8 (4.4, 22.0)
	Day 28	1:320 (1:160, 1:400)	1:320 (1:280, 1:640)	48.8 (14.6, 65.6)
	Day 75	1:160 (1:80, 1:200)	1:160 (1:60, 1:200)	22.5 (11.0, 32.4)

*Spot-forming cells (SFC) per 2 × 10⁵ peripheral blood mononuclear cells (PBMCs).

Figure 3. Behavior of VNA Titers across the 106 Subjects over Days 0, 28, and 75.